A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Latest Information Update: 04 Jan 2022
At a glance
- Drugs Sorafenib (Primary) ; Spartalizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 30 Mar 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Planned End Date changed from 3 Feb 2020 to 27 Feb 2020.
- 24 Feb 2020 Planned primary completion date changed from 3 Feb 2020 to 27 Feb 2020.